740 Y-P 产品活性：740 Y-P (740YPDGFR; PDGFR 740Y-P) 是一个有效的，具有细胞渗透性的 PI3K 激活剂。740 Y-P 很容易结合含有 p85 的 N- 和 C- 末端 SH2 结构域的 GST 融合蛋白，但不能单独结合 GST。 产品来源： https://www.medchemexpress.cn/740_Y-P.html 研究领域：PI3K/Akt/mTOR | Autophagy 作用靶点：PI3K | Autophagy In Vitro: 740 Y-P (50 μg/mL; 48 hours) specificly stimulates mitogenesis in medium is better than EGF or FGF at stimulating entry into S-phase, it shows the percentage of cells in S-phase for 48.3% in C2 cells. Additionally, LY294002 (HY-10108) or Wortmannin (HY-10197) potently inhibits the mitogenic response stimulated by the peptide.740 Y-P (1 μg/mL) stimulates mitogenesis at the lowest concentration tested. The peptide stimulates mitogenesis in both the presence and absence of serum (0.5%), and in the former instance a maximal response observed at 50 μg/mL. 740Y-P to stimulate mitogenesis is highly specific and not a general feature of a cell permeable SH2 domain binding peptides.740 Y-P (30 μM; 24 hours) remarkably inhibits the level of LC3-II/LC3-I in GO-induced PC12 cells. In Vivo: 740 Y-P is not only internalised in living cells but can also interact with p85 in vivo.740 Y-P (intraperitoneal injection; 10 mg/kg; 6 weeks) decreases the degree of ROS levels in Aβ(25-32) treated hippocampal tissues and increases the extent of AKT and PI3K phosphorylation in alzheimer’s disease (AD) rat model. 相关产品：Bioactive Compound Library Plus | Peptide Library | 3-Methyladenine | LY294002 | Quercetin | Alpelisib | Wortmannin | AZD-7648 | Buparlisib | Copanlisib | Dactolisib | Idelalisib | Pictilisib | Inavolisib | Duvelisib | SAR405 | α-Linolenic acid | Eganelisib | YM-201636 | Recilisib | Omipalisib | Isorhamnetin | PI-103 | Taselisib | Fimepinostat | Vps34-IN-1 | 1-Deoxynojirimycin | hSMG-1 inhibitor 11j | iMDK | GSK2636771 | Gallein 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。